A practice transformation model to improve lung cancer care.

Authors

null

Daisy E. Escobar

University of South Alabama, Mobile, AL

Daisy E. Escobar, Mohd Khushman, Jennifer Young Pierce, Cathy Tinnea, Austin Cadden, Debra Wujcik, Susie Owenby, Sachin Gopalkrishn Pai

Organizations

University of South Alabama, Mobile, AL, Mitchell Cancer Institute, Mobile, AR, University of South Alabama, Mitchell Cancer Institute, Mobile, AL, Mitchell Cancer Institute, Mobile, AL, Carevive, Inc., Nashville, TN, Carevive Systems, Inc, Miami, FL, Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL

Research Funding

Pharmaceutical/Biotech Company
Genentech.

Background: Lung cancer has the highest cause of cancer death, treatment of which is both complicated and expensive. Emerging actionable biomarkers and treatments provide both opportunity and treatment challenges. Adherence to evidence-based treatment and advanced care discussions add value to care. Oncology practices need to document the above to participate in value-based care reimbursement models. A Practice Transformation (PT) model was implemented to address quality and cost issues. Methods: After IRB approval, baseline data on lung cancer patients diagnosed during a 6-month period (Jul-Dec 2017) were collected through chart abstraction and treatment planning surveys. Rates of molecular testing ordered, results available at time of treatment decision-making, guideline concordant treatment decisions, and documentation of advanced care discussions were presented to the PT team. After education on recent clinical trial results and NCCN treatment guidelines, the PT team determined strategies for change. The PT team met after two 3-month periods of PT for education updates and progress reports. Data was compared on newly diagnosed patients during a 6-month period (Jul-Dec 2018), one year after the baseline period. Results: A total of forty-two patients were diagnosed in two 6-month periods, baseline and study period. Average age was 65 years, 57% male, 71% Caucasian, 95% ever smokers, 71% adenocarcinoma histology. Rate of ordering any molecular testing was (16/19) 84% in the baseline period vs (20/23) 86% in the study period. However, extended molecular testing increased from 16% (3/19) to 60% (12/20), p = .05 Fishers exact test. At treatment initiation, evidence-based treatment selections went from 47% to 52%. Documentation of advanced care discussions, 42% (8/19) to 56% (13/23), did not change significantly. Conclusions: A PT model that included education, and two cycles of implementation and feedback, resulted in increased molecular testing to inform evidence-based treatment selections. Increased awareness of the lack of documentation of advanced care discussions provides opportunity for continued improvement to effect quality care.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cost, Value, and Policy; Health Equity and Disparities

Track

Cost, Value, and Policy,Health Care Access, Equity, and Disparities

Sub Track

Value/Cost of Care

Citation

J Clin Oncol 37, 2019 (suppl 27; abstr 92)

DOI

10.1200/JCO.2019.37.27_suppl.92

Abstract #

92

Poster Bd #

G7

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Annual Meeting

The impact of end-of-life quality metrics on date of death and hospice documentation over time.

First Author: Divya Deepak

Abstract

2021 ASCO Annual Meeting

The evaluation of a digital solution to improve the implementation of NCCN guidelines.

First Author: Matthew Stewart Prime

First Author: Sujith Puskoor

First Author: Swathi Kanakamedala